# A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

> **NCT01858935** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ND-L02-s0201 Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01858935
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2017-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01858935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01858935, "A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01858935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*